When you look at the real facts about the viral load, it will send shivers down your spine.
The # the lab tests give us is copies per milliliter.
That's how many copies show up in a milliliter of your blood.
You have about 6 quarts of blood in your body.
That's about 5678 milliliters.
So, let's say your viral load is 2 million.
That's 2 million per milliliter.
So that means there are 11,356,000,000 (about 11 and 1/3 billion) virus copies in your entire body, and given the fact that they congregate in the liver, and not at the spot where they are taking the blood sample, probably more than that.
The important thing is, what's happening with your ALT and AST. Viral load can change in a few hours, just get upset and the little bounders multiply like crazy. ALT and AST, on the other hand, seem to be a bit more steady.
The best time to get your viral load tested is when you're feeling good, and not stressed out. Don't go the day after you lose it and scream bloody murder and throw things and put holes in walls! LOL
As a medical device, we have an enduring opportunity as our Hemopurifier® is uniquely positioned as an adjuvant to either interferon-based standard of care (SOC) or emerging all-antiviral drug regimens. And, unlike adjunct drug strategies, the Hemopurifier® performs without adding drug toxicity. In studies conducted in India, a three-treatment Hemopurifier® protocol administered in combination with interferon-based SOC resulted in undetectable HCV levels in as little at seven days in hard to treat genotype-1 patients. The studies also documented the ability of the Hemopurifier® to capture as many as 300 billion copies of HCV during a single six-hour treatment. In addition to augmenting the early viral kinetic response to drug therapy, the Hemopurifier® is a candidate solution for viral rebound patients who traditionally are forced to discontinue therapy once HCV establishes resistance to their drug regimens. Such a solution would address a significant unmet medical need in HCV care.
So with a viral load of 2 million, and that meaning you probably have over 12 billion copies in your body, the hemopurifier could wipe them all out in an hour and still make it home for lunch. LOL I'm not sure how the logistics work for viroids within the cells and how long it takes for them to rupture the cell and get back into the bloodstream. However, I could see that with weekly or even monthly treatments with the hemopurifier a person wouldn't need to be concerned about that.
They have been able to put a shunt into the arms of people on dialysis for diabetes and then it is just s matter of hooking you up to a machine. I'm wondering just how it works. I've talked to someone from this company on the phone and they have not been able to get FDA approval on this remarkable treatment.
About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA.
The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.
Aethlon medical is in the process of doing studies here in the US with the purifier. I was so excited to get the email, and then as I continued to read, found they are using it with interferon / ribavirin treatments to bring up the SVR %. By purifying the blood for the first 3 weeks, the SVR rate is improved. I wrote and asked them why they are using it with interferon and not some of the new drugs. I have yet to get an answer.
The difference between Interferon and Harvoni is simple Interferon kills everything. Harvoni targets ONLY the virus and disables the replication cycle. That's why Interferon has so many side effects and Harvoni has hardly any.
As a medical device, we have an enduring opportunity as our Hemopurifier® is uniquely positioned as an adjuvant to either interferon-based standard of care (SOC) or emerging all-antiviral drug regimens. And, unlike adjunct drug strategies, the Hemopurifier® performs without adding drug toxicity. In studies conducted in India, a three-treatment Hemopurifier® protocol administered in combination with interferon-based SOC resulted in undetectable HCV levels in as little at seven days in hard to treat genotype-1 patients. The studies also documented the ability of the Hemopurifier® to capture as many as 300 billion copies of HCV during a single six-hour treatment. In addition to augmenting the early viral kinetic response to drug therapy, the Hemopurifier® is a candidate solution for viral rebound patients who traditionally are forced to discontinue therapy once HCV establishes resistance to their drug regimens. Such a solution would address a significant unmet medical need in HCV care.
So with a viral load of 2 million, and that meaning you probably have over 12 billion copies in your body, the hemopurifier could wipe them all out in an hour and still make it home for lunch. LOL I'm not sure how the logistics work for viroids within the cells and how long it takes for them to rupture the cell and get back into the bloodstream. However, I could see that with weekly or even monthly treatments with the hemopurifier a person wouldn't need to be concerned about that.
They have been able to put a shunt into the arms of people on dialysis for diabetes and then it is just s matter of hooking you up to a machine. I'm wondering just how it works. I've talked to someone from this company on the phone and they have not been able to get FDA approval on this remarkable treatment.
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA.
The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.